CJC-1295 vs Adipotide
Head-to-head comparison of CJC-1295 and Adipotide for research applications. Both peptides are studied for Body Composition, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Cjc 1295 | Adipotide |
|---|---|---|
| Category | Growth Hormone Secretagogue | Experimental Fat Loss |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous growth hormone, which in turn increases IGF-1 levels. | Adipotide has a dual-domain design. The homing peptide CKGGRAKDC binds to prohibitin on the surface of endothelial cells in white adipose tissue vasculature (prohibitin is overexpressed on fat tissue blood vessels). |
| Evidence Rating | D — Preclinical | D — Animal/Preclinical Only |
| Clinical Status | Research-only / Not approved for human use | Clinical development discontinued. Preclinical only (primate proof-of-concept). No human trials conducted. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | CRITICAL: Reversible kidney toxicity observed in all primate studies; Mechanism: prohibitin expression in kidney proximal tubule cells causes off-target damage |
| Route | Subcutaneous | Subcutaneous injection |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 250-1000 mcg per injection (EXPERIMENTAL — NO ESTABLISHED HUMAN DOSE) |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Once daily |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~3,200 g/mol |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~2-4 hours (estimated) |
Overview
CJC-1295 and Adipotide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
Adipotide — Mechanism & Evidence
Adipotide (FTPP) is a chimeric peptidomimetic (MW ~3,200 g/mol) composed of a prohibitin-targeting domain (CKGGRAKDC) linked to a proapoptotic domain D(KLAKLAK)2. Clinical development was discontinued due to reversible kidney toxicity observed in primate studies.
Key claims: Rapid and significant fat loss; Selectively targets fat tissue vasculature; Improves metabolic parameters.
Shared Research Applications
Both peptides are studied for: Body Composition.
CJC-1295 is also researched for: Anti-Aging.
Adipotide is also researched for: no additional unique applications.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
Adipotide: CRITICAL: Reversible kidney toxicity observed in all primate studies Mechanism: prohibitin expression in kidney proximal tubule cells causes off-target damage Elevated BUN and creatinine during treatment; reversed after discontinuation
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
CJC-1295 and Ipamorelin: Human Evidence and Limits
This reference separates what human trials, animal models, and analytical chemistry show about CJC-1295 and ipamorelin from vendor marketing, assessing the strength of the human evidence base and combination-specific safety data.
CJC-1295 and Ipamorelin Dosage: Evidence and Risks
This reference reviews the evidence on CJC-1295 and ipamorelin dosing, distinguishing what controlled studies support from what remains speculative or vendor-derived.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe